BCMA Targeted Therapies
J&J goes after another FDA approval for a cancer bispecific
Phil Taylor
BCMA Targeted Therapies, immuno-oncology, Janssen, Johnson & Johnson, multiple myeloma, Oncology, teclistamab
0 Comment
AbbVie jumps on the BCMA train, opting into TeneoOne buy
Phil Taylor
AbbVie, BCMA Targeted Therapies, immuno-oncology, M&A, multiple myeloma, Oncology
0 Comment
FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-cel
Phil Taylor
Abecma, BCMA Targeted Therapies, bluebird bio, Bristol-Myers Squibb, CAR-T therapies, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology
0 Comment
Janssen files its first CAR-T therapy cilta-cel in Europe
Phil Taylor
BCMA Targeted Therapies, CAR-T therapies, immuno-oncology, Janssen, Johnson & Johnson, multiple myeloma, Oncology
0 Comment